ARTICLE | Management Tracks
Leading China biotechs Everest, CStone announce CEO departures
Plus updates from BD, Sema4, Nordic Nanovector and more
August 26, 2022 10:47 PM UTC
A pair of closely watched Chinese biotechs announced the departure of their CEOs late this week, with Everest saying farewell to Kerry Blanchard and Frank Jiang leaving CStone.
In his two years at Everest Medicines Ltd. (HKEX:1952), the former Eli Lilly and Co. (NYSE:LLY) executive led the company to a $519 million IPO on the Hong Kong stock exchange, one of the exchange’s largest ever debuts, and its first drug approval. President and CFO Ian Woo became interim CEO of the company, which said it expects to have a new leader in place within a month...